Organization
GoBroad Hospital
7 clinical trials
Clinical trial
Autologous and Donor-derived CD7 CAR T-cell Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma: a Single-center, Open-label, Phase Ⅰ/Ⅱ Clinical TrialStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia：a Single-center, Open-label, Non-randomised, Single-arm Phase Ⅰ Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-06-15
Clinical trial
Pragmatic Clinical Trial of CD19 and CD22 CAR T-cell Sequential Therapy Versus Single CD19 CAR T-cell Bridging to Transplantation for Patients With Refractory or Relapsed B-cell Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2042-12-01
Clinical trial
Safety, Tolerability and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allogeneic Haematopoietic Stem Cell Transplantation and Sequential Donor-derived CD22 CAR Therapy in Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia: a Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-06-15
Clinical trial
A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast CancerStatus: Not yet recruiting, Estimated PCD: 2027-07-01
Clinical trial
Cytokine-induced Killer(CIK) Cell Therapy and Its Impact on Early Functional Exhaustion of Chimeric Antigen Receptor-T(CAR-T) Cells in Relapsed or Refractory Acute B-Lymphoblastic Leukemia: A Prospective StudyStatus: Not yet recruiting, Estimated PCD: 2025-05-30
Clinical trial
CD5 Chimeric Antigen Receptors (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: a Single-center, Open-label, Non-randomized, Phase 1/2 Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2025-12-31